We believe that in the current clinical guidelines, patients with relatively high immunogenicity of gastric cancer types can be treated with PD-L1 inhibitors to achieve better efficacy under the premise of excluding some cases of acute side effects. The gene discussed is CD274; the disease is gastric cancer.